Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- US Department of Veterans Affairs
- Enrollment
- 220
- Locations
- 1
- Primary Endpoint
- Rate of Adherence to Guideline Prescription
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The overall objective of the proposed pilot study is to begin evaluation of two methods for promoting adherence to guidelines for beta-blocker therapy in heart failure. The design includes site level baseline measurement, feedback, remeasurement after six months, and randomized (by site) comparison samples. The setting is VA sites, with intervention directed at the pharmacy.
Detailed Description
Current evidence-based guidelines in VA recommend one of three beta-blockers (carvedilol, metoprolol succinate, or bisoprolol) that have been shown to reduce mortality in heart failure patients with systolic dysfunction, with recommended target doses. However, Pharmacy Benefits Management (PBM) data indicate that prescribing for beta-blockers in heart failure patients that is not in accordance with guidelines is substantial, both in terms of the agent selected and the dose. Sites will be recruited and randomized to two different intensities of intervention to promote adherence to guidelines.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males and females
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Rate of Adherence to Guideline Prescription
Time Frame: 6 months
full adherence to guideline medication and dose
Secondary Outcomes
- Progress Toward Adherence to Guideline Prescription(6 months)